Genitourinary Cancers Clinical Trials & Research at Providence Medical Group

Providence Medical Group is currently enrolling patients for the following genitourinary cancers clinical trials:

A study for patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) (CAPItello-280)

Treatment agent: Capivasertib + docetaxel vs placebo + docetaxel
Physician: Wes Lee, MD
Study Coordinator: Teresa Lund // teresa.lund@stjoe.org // 707-521-3830
Study Resources: Study of Capivasertib + Docetaxel vs Placebo + Docetaxel as Treatment for Metastatic Castration Resistant Prostate Cancer (mCRPC) - Full Text View - ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center Santa Rosa, CA

NRG-GU010 Guidance Study Phase III Randomized Trial of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification And Intensification Clinical Trial Evaluation

Treatment agent: Radiotherapy +/- Androgen Deprivation Therapy (ADT)
Physician: Michael N. Corradetti
Study Coordinator: Beatrice Becker // beatrice.becker@providence.org // 707-932-5164
Study Resources: https://clinicaltrials.gov/study/NCT03488693
Sponsor: National Cancer Institute (NCI) / NRG Oncology Clinical Trials
Location: Providence Queen of the Valley Medical Center, Napa, CA

A study for patients with hisk risk non muscle invasive bladder cancer

Treatment agent: TAR-200 in Combination with Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guerin (BCG)
Physician: YaoYao Pollock, MD
Study Coordinator: Teresa Lund // teresa.lund@stjoe.org // 707-521-3830
Study Resources: A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer - Full Text View - ClinicalTrials.gov
Sponsor: Janssen Research and Development, LLC
Location: Providence Cancer Center Santa Rosa, CA

An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (SGNDV-001/KN-D74)

Treatment agent: Disitamab Vedotin + Pembrolizumab vs Chemotherapy
Physician: Ian Anderson, MD
Study Coordinator: Teresa Lund // teresa.lund@stjoe.org // 707-521-3830
Study Resources: https://clinicaltrials.gov/study/NCT05911295
Sponsor: SeaGen Biotech
Location: Providence Cancer Center Santa Rosa, CA